Morphosys facilitates research and development activities by partnering with pharmaceutical and biotech companies.

In February 2024, the company announced that it was entering into a Business Combination Agreement with Novartis, which will see Novartis obtain exclusive, worldwide rights to develop and commercialize pelabresib, an investigational BET inhibitor, and tulmimetostat, an investigational next-generation dual inhibitor of EZH2 and EZH1, across all indications.